期刊文献+

乳酸-羟基乙酸共聚物多肽蛋白类药物微球控释系统的突释与控制 被引量:4

Burst release and control of the delivery system of protein/peptide drug loaded poly(lactic-co-glycolic acid) microspheres
暂未订购
导出
摘要 背景:突释问题是限制多肽蛋白类微球广泛应用的一个关键技术问题,已经成为PLGA微球控释系统面临的一个亟待解决的问题。目的:分析近年来国内外对乳酸-羟基乙酸共聚物多肽蛋白类药物微球的突释与控制的研究,对突释的原因、影响突释的因素以及减少突释的方法与措施进行了详细的介绍。方法:应用计算机检索CNKI和PubMed数据库中1999-01/2010-12关于乳酸-羟基乙酸共聚物多肽蛋白类药物微球控释系统研究的文章,在标题和摘要中以"聚乳酸-羟基乙酸;多肽;蛋白;微球;突释;控制"或"PLGA;peptide;protein;microspheres;burst release;control"为检索词进行检索。通过阅读标题和摘要进行初选,排出较陈旧和重复研究文献,保留符合纳入标准的文献24篇。结果与结论:对乳酸-羟基乙酸共聚物多肽蛋白类药物微球突释机制的理解,可以更好地实现对微球突释的控制,以扩大多肽蛋白类药物在临床上的应用。PLGA的性质、微球的制备方法、微球的制备参数都在不同程度上影响微球的突释,并且可能是多因素协同作用。通过对上述各种因素加以适当控制,可在一定程度上减少微球的突释率。通过该方面的机制研究对指导新药开发具有重要意义。 BACKGROUND:Burst release is key technology that limits the wide application of protein/peptide microspheres.It should be a problem to be solved.OBJECTIVE:To make a detailed introduction about burst release reason,influence factors and reduction methods after analyzing recent progress of burst release and control of protein/peptide drug loaded poly(lactic-co-glycolic acid)(PLGA).METHODS:Relevant articles in PubMed and CNKI published 1999-01/2010-12 were searched by computer with the key words of "PLGA,peptide,protein,microspheres,burst release,control" in Chinese and English.Articles addressing originally identification,reliability,general analysis,and high correlation were included.Exclusive criteria:repetitive and obsolescent articles.A total of 24 articles were reserved for review.RESULTS AND CONCLUSION:We need to comprehend mechanism of burst release of protein/peptide microspheres to realize enlargement application.Burst release was influenced by multifactors,such as characters of PLGA,preparation methods and preparation parameters.Burst release could be reduced some degree by the control of the above mentioned.It is very important to research of new drugs.
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2011年第38期7177-7180,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
  • 相关文献

参考文献24

  • 1王丹.多肽及蛋白类药物微球的载体材料、制备以及突释现象[J].中国组织工程研究与临床康复,2008,12(10):1931-1934. 被引量:13
  • 2贾雷,房泽海.制剂新技术在蛋白多肽类药物中的应用[J].中国药业,2009,18(18):80-80. 被引量:5
  • 3尹东锋,钟延强.影响聚乳酸、聚羟基乙酸嵌段共聚物微球中蛋白、多肽类药物释放的因素[J].中国药学杂志,2006,41(14):1049-1052. 被引量:2
  • 4Tan ML,Choong PF,Dass CR.Recent developments in liposomes,microparticles and nanoparticles for protein and peptide drug delivery.Peptides.2010;31(1):184-193.
  • 5Mao S,Xu J,Cai C,et al.Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres.Int J Pharm.2007;334(1-2):137-148.
  • 6Raman C,Berkland C,Kim K,et al.Modeling small-molecule release from PLG microspheres:effects of polymer degradation and nonuniform drug distribution.J Control Release.2005;103(1):149-158.
  • 7Giteau A,Venier-Julienne MC,Aubert-Pou?ssel A,et al.How to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm.2008;350(1-2):14-26.
  • 8Giunchedi P,Conti B,Genta I,et al.Emulsion spray-drying for the preparation of album in loaded PLGA microspheres.Drug Dev Ind Pharm.2001;27(7):745-750.
  • 9Matsuyama T,Morita T,Horikiri Y,et al.Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant.J Control Release.2006; 110 (2):347-359.
  • 10Paillard-Giteau A,Tran VT,Thomas O,et al.Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique.Eur J Pharm Biopharm.2010;75(2):128-136.

二级参考文献86

共引文献17

同被引文献68

  • 1叶美娣,郑彩虹.乳酸-羟基乙酸共聚物(PLGA)微球控释系统的突释[J].中国现代应用药学,2005,22(5):371-374. 被引量:9
  • 2孙家英,张立武,梅虎,梁桂兆,周原.星形聚合物的研究与应用进展[J].化工进展,2006,25(3):281-285. 被引量:19
  • 3谢兰桂,刘玉玲.多肽蛋白类药物的长效注射微球突释控制技术研究进展[J].中国医药工业杂志,2006,37(9):639-643. 被引量:6
  • 4任海霞,朱家壁,汤玥.微球制剂的应用研究进展[J].药学进展,2007,31(2):59-63. 被引量:22
  • 5Nahar M, JaJn N K. Preparation,characterization and evaluation of targeting potential of amphotericin bloaded engineered PLGA nanoparticles [ J ]. Pharm Res ,2009,26:2588 - 2598.
  • 6Allison S D. Effect of structural relaxation on the preparation and drag release behavior of poly( lacticco-glycolic) acid microparticle drug delivery systems [J]. J Pharm Sci,2008,97:2022-2035.
  • 7Padrutt I, Lutz TA, Reusch CE, et al. Effects of the glucagon- like peptide- 1 (GLP- 1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats [J].Res Vet Sci, 2015, 99: 23-29.
  • 8Grossman SS. Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes [J]. Adv Ther, 2014, 31 (3) : 247-263.
  • 9Zhang B, He D, Fan Y, et al. Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate [J]. PLoS one, 2014, 9 (1) : e86064.
  • 10Li K, Yu L, Liu X, et al. A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel [J]. Biomaterials, 2013, 34(11): 2834-2842.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部